Depressão e fadiga em mulheres com Esclerose Múltipla, após fim do isolamento social pela pandemia da Covid-19
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Dec 23, 2023
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Verificar o comportamento dos sintomas depressivos, da fadiga, do equilíbrio postural e da caminhada em mulheres com Esclerose Múltipla (EM), antes do isolamento e após o fim do isolamento social, medida instaurada pela pandemia da Covid-19. Métodos: A amostra desse estudo longitudinal, prospectivo, incluiu 15 mulheres com EM. Pela escala de doença determinada pelo paciente (PDDS) categorizamos dois grupos, sem incapacidade ao caminhar (GSI) e com incapacidade (GCI). Avaliamos, em dois momentos, a presença de sintomas depressivos pelo inventário de Beck (BECK-II), severidade da fadiga (FSS) e seu impacto (MFIS), equilíbrio postural (posturografia) e caminhada (teste de caminhada de 25 pés). Para comparar as variáveis coletadas nos diferentes momentos utilizamos teste t pareado. Resultados: Encontramos melhoras significativas e tamanho de efeito moderado (p<0.05 e ES>0.50) nos sintomas depressivos e fadiga, do GCI, após fim do isolamento. Não encontramos diferenças significativas nas demais comparações. Conclusão: Como principal achado nosso estudo mostrou que para o GCI o retorno ao convívio social foi o suficiente para uma melhora significativa de sintomas depressivos e fadiga. Reforçamos, assim, a importância do cuidado em saúde direcionado ao domínio psicossocial na população de mulheres com EM e incapacidade ao caminhar.
##plugins.themes.bootstrap3.article.details##
Como Citar
MachadoE. F. A., MoraesA. G., & DavidA. C. de. (2023). Depressão e fadiga em mulheres com Esclerose Múltipla, após fim do isolamento social pela pandemia da Covid-19. Revista Eletrônica Acervo Saúde, 23(12), e14737. https://doi.org/10.25248/reas.e14737.2023
Seção
Artigos Originais
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
ALSCHULER KN, et al. Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic. Mult Scler Relat Disord., 2021; 47: 102618.
2. ALTUNAN B, et al. Coping with stress during the first wave of the COVID-19 pandemic by Turkish people with Multiple Sclerosis: The relationship between perceived stress and quality of life. Mult Scler Relat Disord., 2021; 53: 103039.
3. ANDREU-CARAVACA L, et al. The impact of COVID-19 home confinement on neuromuscular performance, functional capacity, and psychological state in Spanish people with Multiple Sclerosis. Mult Scler Relat Disord., 2021; 53: 103047.
4. BONAVITA S, et al. Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. Eur J Neurol., 2021; 28(10): 3396-3402.
5. CAPUANO R, et al. Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience? J Neurol., 2021; 268(3): 743-750.
6. CAPUTO EL e REICHERT FF. Studies of Physical Activity and COVID-19 During the Pandemic: A Scoping Review. J Phys Act Health, 2020; 17(12): 1275-1284.
7. CHALAH MA, et al. Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation. Front Cell Neurosci., 2015; 9: 460.
8. CHIARAVALLOTI ND, et al. The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. J Neurol., 2021; 268(5): 1598-1607.
9. COHEN J. Statistical power analysis for the behavioral sciences Lawrence Earlbaum Associates. 20th–. Published online 1988.
10. COMPSTON A e COLES A. Multiple sclerosis. The Lancet, 2008; 372(9648): 1502-1517.
11. COSTABILE T, et al. COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol., 2021; 28(10): 3375-3383.
12. DONZÉ C e MASSOT C. Rehabilitation in multiple sclerosis in 2021. Presse Médicale, 2021; 50(2): 104066.
13. DOSHI A e CHATAWAY J. Multiple sclerosis, a treatable disease. Clin Med., 2017; 17(6): 530-536.
14. FEINSTEIN A, et al. The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study. J Neurol., 2022; 269(12): 6202-6210.
15. FIORILLO A, et al. Effects of the lockdown on the mental health of the general population during the COVID-19 pandemic in Italy: Results from the COMET collaborative network. Eur Psychiatry J Assoc Eur Psychiatr., 2020; 63(1): e87.
16. FISCHER JS, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler Houndmills Basingstoke Engl., 1999; 5(4): 244-250.
17. FISK JD, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci J Can Sci Neurol., 1994; 21(1): 9-14.
18. GOMES-OLIVEIRA MH, et al. Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. Rev Bras Psiquiatr Sao Paulo Braz, 2012; 34(4): 389-394.
19. HOHOL MJ, et al. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology, 1995; 45(2): 251-255.
20. KOOPMANN A, et al. The Effects of the Lockdown during the COVID-19 Pandemic on Alcohol and Tobacco Consumption Behavior in Germany. Eur Addict Res., 2021; 27(4): 242-256.
21. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983; 33(11): 1444-1452.
22. LEARMONTH YC, et al. Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale. J Neurol Sci., 2013; 331(1-2): 102-107.
23. LEARMONTH YC, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol., 2013; 13: 37.
24. LEE G e PARK AE. Development of a more robust tool for postural stability analysis of laparoscopic surgeons. Surg Endosc., 2008; 22(4): 1087-1092.
25. MORRIS-BANKOLE H e HO AK. The COVID-19 Pandemic Experience in Multiple Sclerosis: The Good, the Bad and the Neutral. Neurol Ther., 2021; 10(1): 279-291.
26. MOTL RW, et al. Symptoms, self-efficacy, and physical activity among individuals with multiple sclerosis. Res Nurs Health, 2006; 29(6): 597-606.
27. MOTOLESE F, et al. The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis. Front Neurol. 2020;11:580507.
28. PATEJDL R, et al. Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev. 2016;15(3):210-220.
29. POLMAN CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
30. RAYMAKERS JA, et al. The assessment of body sway and the choice of the stability parameter(s). Gait Posture. 2005;21(1):48-58.
31. SACCO R, et al. Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. Eur J Neurol. 2016;23(4):744-750.
32. SCOPPA F, et al. Clinical stabilometry standardization: Basic definitions – Acquisition interval – Sampling frequency. Gait Posture. 2013;37(2):290-292.
33. SOLARO C, et al. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. CNS Drugs. 2018;32(2):117-133.
34. STOJANOV A, et al. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak. Mult Scler Relat Disord. 2020;45:102407.
35. THOMPSON AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
36. VAN EMMERIK REA, et al. Postural control in women with multiple sclerosis: effects of task, vision and symptomatic fatigue. Gait Posture. 2010;32(4):608-614.
37. VERCELLINO M, et al. Impact of COVID-19 lockdown on progressive multiple sclerosis patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2022;43(5):2943-2946.
38. WEILAND TJ, et al. Clinically Significant Fatigue: Prevalence and Associated Factors in an International Sample of Adults with Multiple Sclerosis Recruited via the Internet. PLOS ONE. 2015;10(2):e0115541.
39. WILSKI M, et al. Mental Health Status of People with Multiple Sclerosis during the COVID-19 Pandemic. J Clin Med. 2022;11(3):576.
40. ZANGHÌ A, et al. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Mult Scler Relat Disord. 2020;46:102561.
2. ALTUNAN B, et al. Coping with stress during the first wave of the COVID-19 pandemic by Turkish people with Multiple Sclerosis: The relationship between perceived stress and quality of life. Mult Scler Relat Disord., 2021; 53: 103039.
3. ANDREU-CARAVACA L, et al. The impact of COVID-19 home confinement on neuromuscular performance, functional capacity, and psychological state in Spanish people with Multiple Sclerosis. Mult Scler Relat Disord., 2021; 53: 103047.
4. BONAVITA S, et al. Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. Eur J Neurol., 2021; 28(10): 3396-3402.
5. CAPUANO R, et al. Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience? J Neurol., 2021; 268(3): 743-750.
6. CAPUTO EL e REICHERT FF. Studies of Physical Activity and COVID-19 During the Pandemic: A Scoping Review. J Phys Act Health, 2020; 17(12): 1275-1284.
7. CHALAH MA, et al. Fatigue in Multiple Sclerosis: Neural Correlates and the Role of Non-Invasive Brain Stimulation. Front Cell Neurosci., 2015; 9: 460.
8. CHIARAVALLOTI ND, et al. The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. J Neurol., 2021; 268(5): 1598-1607.
9. COHEN J. Statistical power analysis for the behavioral sciences Lawrence Earlbaum Associates. 20th–. Published online 1988.
10. COMPSTON A e COLES A. Multiple sclerosis. The Lancet, 2008; 372(9648): 1502-1517.
11. COSTABILE T, et al. COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol., 2021; 28(10): 3375-3383.
12. DONZÉ C e MASSOT C. Rehabilitation in multiple sclerosis in 2021. Presse Médicale, 2021; 50(2): 104066.
13. DOSHI A e CHATAWAY J. Multiple sclerosis, a treatable disease. Clin Med., 2017; 17(6): 530-536.
14. FEINSTEIN A, et al. The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study. J Neurol., 2022; 269(12): 6202-6210.
15. FIORILLO A, et al. Effects of the lockdown on the mental health of the general population during the COVID-19 pandemic in Italy: Results from the COMET collaborative network. Eur Psychiatry J Assoc Eur Psychiatr., 2020; 63(1): e87.
16. FISCHER JS, et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler Houndmills Basingstoke Engl., 1999; 5(4): 244-250.
17. FISK JD, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci J Can Sci Neurol., 1994; 21(1): 9-14.
18. GOMES-OLIVEIRA MH, et al. Validation of the Brazilian Portuguese version of the Beck Depression Inventory-II in a community sample. Rev Bras Psiquiatr Sao Paulo Braz, 2012; 34(4): 389-394.
19. HOHOL MJ, et al. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology, 1995; 45(2): 251-255.
20. KOOPMANN A, et al. The Effects of the Lockdown during the COVID-19 Pandemic on Alcohol and Tobacco Consumption Behavior in Germany. Eur Addict Res., 2021; 27(4): 242-256.
21. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983; 33(11): 1444-1452.
22. LEARMONTH YC, et al. Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale. J Neurol Sci., 2013; 331(1-2): 102-107.
23. LEARMONTH YC, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol., 2013; 13: 37.
24. LEE G e PARK AE. Development of a more robust tool for postural stability analysis of laparoscopic surgeons. Surg Endosc., 2008; 22(4): 1087-1092.
25. MORRIS-BANKOLE H e HO AK. The COVID-19 Pandemic Experience in Multiple Sclerosis: The Good, the Bad and the Neutral. Neurol Ther., 2021; 10(1): 279-291.
26. MOTL RW, et al. Symptoms, self-efficacy, and physical activity among individuals with multiple sclerosis. Res Nurs Health, 2006; 29(6): 597-606.
27. MOTOLESE F, et al. The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis. Front Neurol. 2020;11:580507.
28. PATEJDL R, et al. Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev. 2016;15(3):210-220.
29. POLMAN CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
30. RAYMAKERS JA, et al. The assessment of body sway and the choice of the stability parameter(s). Gait Posture. 2005;21(1):48-58.
31. SACCO R, et al. Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. Eur J Neurol. 2016;23(4):744-750.
32. SCOPPA F, et al. Clinical stabilometry standardization: Basic definitions – Acquisition interval – Sampling frequency. Gait Posture. 2013;37(2):290-292.
33. SOLARO C, et al. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. CNS Drugs. 2018;32(2):117-133.
34. STOJANOV A, et al. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak. Mult Scler Relat Disord. 2020;45:102407.
35. THOMPSON AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
36. VAN EMMERIK REA, et al. Postural control in women with multiple sclerosis: effects of task, vision and symptomatic fatigue. Gait Posture. 2010;32(4):608-614.
37. VERCELLINO M, et al. Impact of COVID-19 lockdown on progressive multiple sclerosis patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2022;43(5):2943-2946.
38. WEILAND TJ, et al. Clinically Significant Fatigue: Prevalence and Associated Factors in an International Sample of Adults with Multiple Sclerosis Recruited via the Internet. PLOS ONE. 2015;10(2):e0115541.
39. WILSKI M, et al. Mental Health Status of People with Multiple Sclerosis during the COVID-19 Pandemic. J Clin Med. 2022;11(3):576.
40. ZANGHÌ A, et al. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Mult Scler Relat Disord. 2020;46:102561.